Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q06830

UPID:
PRDX1_HUMAN

ALTERNATIVE NAMES:
Natural killer cell-enhancing factor A; Proliferation-associated gene protein; Thioredoxin peroxidase 2; Thioredoxin-dependent peroxide reductase 2; Thioredoxin-dependent peroxiredoxin 1

ALTERNATIVE UPACC:
Q06830; B5BU26; D3DPZ8; P35703; Q2V576; Q5T154; Q5T155

BACKGROUND:
Peroxiredoxin-1, also referred to as Thioredoxin-dependent peroxide reductase 2, is a thiol-specific peroxidase that mitigates oxidative damage by reducing peroxides to water and alcohols. It functions as a crucial antioxidant, protecting cells from oxidative stress and participating in hydrogen peroxide-mediated signaling, potentially affecting growth factor and tumor necrosis factor-alpha signaling cascades.

THERAPEUTIC SIGNIFICANCE:
The exploration of Peroxiredoxin-1's function offers promising avenues for drug discovery. By regulating intracellular concentrations of H2O2, it plays a significant role in cell protection and signaling, making it a compelling target for developing treatments against diseases characterized by oxidative stress and abnormal cell signaling.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.